Samer Al Hadidi, Assistant professor at UAMS Myeloma Center, posted on LinkedIn about recent paper he and colleagues co-authored, titled “Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma” published on American Society of Hematology Blood Advances.
Authors: Bhavesh Mohan Lal, Marah Alzubi, Jawad Alrawabdeh, John D. Shaughnessy, Jr, Fenghuang Zhan, Eric R. Siegel, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Samer Al Hadidi
“Check out recent work published American Society of Hematology Blood Advances.
Prior Exposure to Belantamab, Mafodotin Influences Outcomes with Idecabtagene ,Vicluecel in Patients with Multiple Myeloma.”